247 related articles for article (PubMed ID: 26143613)
1. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.
Frey SE; Winokur PL; Hill H; Goll JB; Chaplin P; Belshe RB
Vaccine; 2014 May; 32(23):2732-9. PubMed ID: 24607004
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
Wilck MB; Seaman MS; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Kleinjan JA; Noble LC; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1361-70. PubMed ID: 20350191
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
[TBL] [Abstract][Full Text] [Related]
10. Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses.
Frey SE; Stapleton JT; Ballas ZK; Rasmussen WL; Kaufman TM; Blevins TP; Jensen TL; Davies DH; Tary-Lehmann M; Chaplin P; Hill H; Goll JB;
J Infect Dis; 2021 Oct; 224(8):1372-1382. PubMed ID: 33675226
[TBL] [Abstract][Full Text] [Related]
11. Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits.
Tree JA; Hall G; Rees P; Vipond J; Funnell SG; Roberts AD
Hum Vaccin Immunother; 2016 Jul; 12(7):1795-801. PubMed ID: 26836234
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
von Sonnenburg F; Perona P; Darsow U; Ring J; von Krempelhuber A; Vollmar J; Roesch S; Baedeker N; Kollaritsch H; Chaplin P
Vaccine; 2014 Sep; 32(43):5696-702. PubMed ID: 25149431
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial.
Arakane R; Nakatani H; Fujisaki E; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
Vaccine; 2015 Nov; 33(46):6340-50. PubMed ID: 26431983
[TBL] [Abstract][Full Text] [Related]
15. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
16. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.
Troy JD; Hill HR; Ewell MG; Frey SE
Vaccine; 2015 Oct; 33(41):5425-5431. PubMed ID: 26319063
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
Kennedy JS; Gurwith M; Dekker CL; Frey SE; Edwards KM; Kenner J; Lock M; Empig C; Morikawa S; Saijo M; Yokote H; Karem K; Damon I; Perlroth M; Greenberg RN
J Infect Dis; 2011 Nov; 204(9):1395-402. PubMed ID: 21921208
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
[TBL] [Abstract][Full Text] [Related]
19. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
Recuenco S; Warnock E; Osinubi MOV; Rupprecht CE
Vaccine; 2017 Aug; 35(34):4315-4320. PubMed ID: 28688782
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
von Krempelhuber A; Vollmar J; Pokorny R; Rapp P; Wulff N; Petzold B; Handley A; Mateo L; Siersbol H; Kollaritsch H; Chaplin P
Vaccine; 2010 Feb; 28(5):1209-16. PubMed ID: 19944151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
